River's Edge Pharmacy argues rehabilitation and seeks early end to probation

River's Edge Pharmacy and CEO Genevieve Benjamin asked the disciplinary petition committee to end the pharmacy’s probation early, saying extensive remediation since the 2017–2020 conduct has brought the operation into compliance.

Deputy Attorney General Christina Jarvis summarized a complicated accusation that involved purchases of discounted oncology drugs intended for specific physician programs, transfers to third parties, receipt of drugs from an unlicensed source, and recordkeeping lapses. The decision imposed a four‑year probation (effective Aug. 24, 2022). Jarvis noted petitioners reimbursed investigation costs (about $70,000 in 2024) and paid an administrative fine and that the pharmacy had engaged consultants and made policy changes while losing some PBM contracts during probation.

CEO Genevieve Benjamin testified that the company created an independent compliance department, added a performance improvement manager, retained consultant Dr. Raffi Simonian for intensive monthly then quarterly audits, and installed tracking systems for sterile compounding and drug pedigree. Consultant Simonian testified he conducted roughly 25 in‑person inspections, produced detailed reports and found the pharmacy operating at a high level of compliance. Compliance officer Chi Hsu described invoice and source audits and weekly PIC meetings to maintain accountability.

Petition counsel argued termination of probation would restore patient access lost when PBMs terminated contracts and would allow River's Edge to recontract for services, while Jarvis left the ultimate decision to the board and suggested that, if reinstated, careful probation conditions or monitoring remain appropriate. The ALJ closed the record and submitted the matter for board deliberation in closed session.